Unlock stock picks and a broker-level newsfeed that powers Wall Street.

HKSE - Delayed Quote HKD

Lepu Biopharma Co., Ltd. (2157.HK)

Compare
3.580
+0.210
+(6.23%)
As of 9:56:25 AM GMT+8. Market Open.
Currency in CNY All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
225,352
225,352
15,572
--
--
Cost of Revenue
28,277
28,277
2,005
--
--
Gross Profit
197,075
197,075
13,567
--
--
Operating Expense
581,404
581,404
655,743
943,763
449,414
Operating Income
-384,329
-384,329
-642,176
-943,763
-449,414
Net Non Operating Interest Income Expense
-7,968
-7,968
-474
870
-81,053
Pretax Income
-30,301
-30,301
-699,441
-1,028,869
-613,448
Net Income Common Stockholders
-22,096
-22,096
-689,052
-1,010,996
-581,849
Diluted NI Available to Com Stockholders
-22,096
-22,096
-689,052
-1,010,996
-581,849
Basic EPS
-0.01
-0.01
-0.42
-0.61
-0.35
Diluted EPS
-0.01
-0.01
-0.42
-0.61
-0.35
Basic Average Shares
1,659,445
1,659,445
1,640,825
1,658,545.838
1,658,545.838
Diluted Average Shares
1,659,445
1,659,445
1,640,825
1,658,545.838
1,658,545.838
Total Operating Income as Reported
4,796
4,796
-704,482
-1,009,636
-520,351
Total Expenses
609,681
609,681
657,748
943,763
449,414
Net Income from Continuing & Discontinued Operation
-22,096
-22,096
-689,052
-1,010,996
-581,849
Normalized Income
-242,486
-242,486
-689,836
-945,035
-508,949
Interest Income
8,049
8,049
8,173
4,143
5,266
Interest Expense
14,677
14,677
7,467
2,696
85,209
Net Interest Income
-7,968
-7,968
-474
870
-81,053
EBIT
-15,624
-15,624
-691,974
-1,026,173
-528,239
EBITDA
86,948
86,948
-596,528
-930,927
-444,125
Reconciled Cost of Revenue
28,277
28,277
2,005
--
--
Reconciled Depreciation
102,572
102,572
95,446
95,246
84,114
Net Income from Continuing Operation Net Minority Interest
-22,096
-22,096
-689,052
-1,010,996
-581,849
Total Unusual Items Excluding Goodwill
220,390
220,390
784
-65,961
-72,900
Total Unusual Items
220,390
220,390
784
-65,961
-72,900
Normalized EBITDA
-133,442
-133,442
-597,312
-864,966
-371,225
12/31/2020 - 2/23/2022

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers